BridgeBio Oncology Therapeutics
Initial Transaction Details
Transaction Date
April 2024
Purpose of Financing
Special Situations
Stage of Company
Mid Stage
Structure of Financing
Equity
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics aims to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
Website